10462-00-7

Upstream product

• 24465-45-0 ethyl 4-phenyl-4-piperidinecarboxylate hydrochloride 
• 77-17-8 Normeperidine 
• 1225591-27-4 ethyl 1-tert-butoxycarbonyl-4-cyclohexylpiperidine-4-carboxylate 

Downstream Products

• 624732-70-3 (4-cyclohexylpiperidin-4-yl)-methanol 
• 312638-87-2 4-cyclohexyl-4-hydroxymethylpiperidine-1-carboxylic acid tert-butyl ester 
• 363192-22-7 4-cyclohexyl-4-formyl-piperidine-1-carboxylic acid tert-butyl ester 
• 1225591-29-6 ethyl 1-[(R)-2-tert-butoxycarbonylamino-3-(4-methoxyphenyl)propionyl]-4-cyclohexylpiperidine-4-carboxylate 
• 1225591-35-4 ethyl 1-[(R)-2-tert-butoxycarbonylamino-3-(3,4-dichlorophenyl)propionyl]-4-cyclohexylpiperidine-4-carboxylate 
• 1403502-84-0 C₂₈H₄₁FN₂O₅ 
• 1225652-94-7 ethyl 1-[(R)-2-tert-butoxycarbonylamino-3-(4-chlorophenyl)propionyl]-4-cyclohexylpiperidine-4-carboxylate 
• 624732-71-4 4-cyclohexyl-piperidine-4-carbaldehyde 

Relevant academic research and scientific papers

MELANOCORTIN RECEPTOR ANTAGONIST COMPOUNDS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS

The present invention relates to novel melanocortin receptor antagonist compounds corresponding to the general formula (I) below, to compositions containing them, to the process for preparing them and to their use in pharmaceutical or cosmetic compositions.

MELANOCORTIN RECEPTOR MODULATORS, PROCESS FOR PREPARING THEM AND USE THEREOF IN HUMAN MEDICINE AND COSMETICS

The present invention relates to novel melanocortin receptor modulators corresponding to the general formula (I) to compositions containing them, to the process for preparing them and to their use in pharmaceutical or cosmetic compositions.

Melanocortin receptor ligands

The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein preferably R is substituted aryl, W1 is a carbocyclic unit, and W2 is a heteroatom comprising unit.

Melanocortin receptor ligands

The present invention relates to compounds which comprise a 4-substituted piperidine ring linked to a substituted or unsubstituted hydrocarbyl ring. The compounds, including all enatiomeric and diasteriomeric forms and pharmaceutically acceptable salts thereof, have the formula: wherein preferably R is substituted aryl, W is a pendant unit having the formula: -L-Q L is a linking unit, Q is preferably a cyclic hydrocarbyl unit; W1 is preferably a carbocyclic unit and W2 is a heteroatom comprising unit.

Substituted piperidines as melanocortin-4 receptor agonists

Certain novel substituted piperidine compounds are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R). They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Also provided are methods of treating sexual dysfunction with a compound that is a selective agonist of MC-4R over any other human melanocortin receptor.